Featured 13F manager
DAFNA Capital Management LLC Nathan Fischel
Los Angeles, CA 20 processed 13Fs on this site · 2021 Q3–2026 Q2
- $524M
- 88 Positions
- 2026 Q2
- +19.1% QoQ
- Top 5 40.2%
Nathan Fischel files DAFNA Capital Management LLC as a Form 13F. The latest book is 2026 Q2 at $524M, up 19.1% QoQ, led by Revolution Medicines, Spdr S&P Biotech ETF, and Compass Pathways.
Portfolio
top 5 40.2% · top 10 56.2%
- RVMD - Revolution Medicines 20.1%
- XBI - Spdr S&P Biotech ETF 5.9%
- CMPS - Compass Pathways 5.4%
- STXS - Stereotaxis 4.5%
- NKTR - Nektar Therapeutics 4.3%
- DNLI - Denali Therapeutics 3.6%
- IDYA - Ideaya Biosciences 3.5%
- ATRC - Atricure 3.2%
- XENE - Xenon Pharmaceuticals 2.9%
- CYTK - Cytokinetics 2.8%
- RCUS - Arcus Biosciences 2.6%
- ASND - Ascendis Pharma A/S 2.5%
- Other 38.7%
AUM over time
Book
| XBI - Spdr S&P Biotech ETF | 12.85% | Reduce −0.9% | 565,000 | $83.20 | $47M | −5,000 | +$4M |
| Iveric Bio | 6.59% | Hold | 612,975 | $39.34 | $24M | — | — |
| STXS - Stereotaxis | 5.72% | Hold | 13,680,554 | $1.53 | $21M | — | — |
| Blueprint Medicines | 4.35% | Reduce −3.7% | 251,521 | $63.20 | $16M | −9,714 | +$4M |
| RVMD - Revolution Medicines | 3.75% | Reduce −11.0% | 512,285 | $26.75 | $14M | −63,500 | +$1M |
| NDAQ - Ishares Nasdaq Biotech Indx | 3.56% | Hold | 102,500 | $126.96 | $13M | — | — |
| ASND - Ascendis Pharma A/S | 3.30% | Hold | 135,212 | $89.25 | $12M | — | — |
| Morphic | 3.24% | Add +15.2% | 206,748 | $57.33 | $12M | +27,281 | +$5M |
| IDYA - Ideaya Biosciences | 3.08% | Add +2.4% | 479,820 | $23.50 | $11M | +11,462 | +$5M |
| CYTK - Cytokinetics | 2.97% | Add +20.3% | 332,734 | $32.62 | $11M | +56,239 | +$1M |
| XENE - Xenon Pharmaceuticals | 2.95% | Reduce −11.2% | 280,538 | $38.50 | $11M | −35,554 | −$512K |
| Merus | 2.77% | Add +35.5% | 384,870 | $26.33 | $10M | +100,872 | +$5M |
| SNDX - Syndax Pharmaceuticals | 2.58% | Add +0.8% | 450,873 | $20.93 | $9M | +3,800 | −$5K |
| Karuna Therapeutics | 2.50% | Reduce −46.3% | 42,173 | $216.85 | $9M | −36,400 | −$5M |
| DXCM - Dexcom | 2.37% | Hold | 67,552 | $128.51 | $9M | — | — |
| Sage Therapeutics | 2.32% | Hold | 180,306 | $47.02 | $8M | — | — |
| NBIX - Neurocrine Biosciences | 1.92% | Hold | 74,615 | $94.30 | $7M | — | — |
| ATRC - Atricure | 1.69% | Hold | 125,529 | $49.36 | $6M | — | — |
| DAWNGBX — | 1.66% | New | 507,100 | $11.94 | $6M | +507,100 | +$6M |
| Dice Therapeutics | 1.62% | Reduce −32.0% | 127,585 | $46.46 | $6M | −60,000 | +$553K |
| NRIX - Nurix Therapeutics | 1.52% | Reduce −1.8% | 556,695 | $9.99 | $6M | −10,000 | +$529K |
| Kalvista Pharmaceuticals | 1.50% | Reduce −0.8% | 611,032 | $9.00 | $5M | −5,000 | +$657K |
| 2seventy Bio | 1.37% | New | 496,416 | $10.12 | $5M | +496,416 | +$5M |
| VKTX - Viking Therapeutics | 1.30% | Reduce −8.0% | 293,655 | $16.21 | $5M | −25,500 | −$554K |
| ARAY - Accuray | 1.29% | Hold | 1,222,358 | $3.87 | $5M | — | — |
| RCUS - Arcus Biosciences | 1.25% | Add +28.8% | 225,717 | $20.31 | $5M | +50,500 | +$1M |
| IPSC - Century Therapeutics | 1.13% | Hold | 1,307,407 | $3.16 | $4M | — | — |
| EWTX - Edgewise Therapeutics | 1.10% | Reduce −29.2% | 519,384 | $7.75 | $4M | −213,855 | −$865K |
| BCRX - Biocryst Pharmaceuticals | 1.10% | Add +3.2% | 569,000 | $7.04 | $4M | +17,500 | −$594K |
| ALEC - Alector | 1.05% | Add +7.8% | 638,938 | $6.01 | $4M | +46,500 | +$173K |
| KURA - Kura Oncology | 1.04% | Add +225.9% | 357,784 | $10.58 | $4M | +248,000 | +$2M |
| Mirati Therapeutics | 0.94% | Add +28.7% | 94,700 | $36.13 | $3M | +21,100 | +$685K |
| BCYC - Bicycle Therapeutics | 0.85% | Hold | 122,200 | $25.52 | $3M | — | — |
| AXGN - Axogen | 0.83% | Hold | 332,103 | $9.13 | $3M | — | — |
| Mediwound | 0.75% | Hold | 257,653 | $10.66 | $3M | — | — |
| TNDM - Tandem Diabetes Care | 0.74% | New | 110,000 | $24.54 | $3M | +110,000 | +$3M |
| Mersana Therapeutics | 0.73% | Add +58.7% | 810,845 | $3.29 | $3M | +299,982 | +$568K |
| AUTL - Autolus Therapeutics | 0.61% | Reduce −20.9% | 930,394 | $2.38 | $2M | −245,756 | +$50K |
| LKFT - Galapagos | 0.59% | Hold | 52,675 | $40.66 | $2M | — | — |
| Adicet Bio | 0.53% | Hold | 797,054 | $2.43 | $2M | — | — |
| Keros Therapeutics | 0.52% | Add +146.2% | 47,661 | $40.18 | $2M | +28,300 | +$1M |
| Regulus Therapeutics | 0.45% | Add +100.0% | 1,111,049 | $1.47 | $2M | +555,494 | +$1M |
| Vigil Neuroscience | 0.44% | Hold | 172,308 | $9.40 | $2M | — | — |
| PRQR - Proqr Therapeutics | 0.42% | Hold | 940,582 | $1.62 | $2M | — | — |
| Lyra Therapeutics | 0.41% | New | 361,084 | $4.11 | $1M | +361,084 | +$1M |
| Mereo Biopharma Group | 0.36% | Reduce −8.0% | 1,009,013 | $1.32 | $1M | −87,500 | +$557K |
| Iteos Therapeutics | 0.36% | Hold | 98,560 | $13.24 | $1M | — | — |
| BWAY - Brainsway | 0.31% | Add +6.5% | 504,681 | $2.28 | $1M | +30,700 | +$319K |
| Sutro Biopharma | 0.31% | Add +186.6% | 242,779 | $4.65 | $1M | +158,079 | +$738K |
| LRMR - Larimar Therapeutics | 0.30% | Add +47.9% | 350,373 | $3.13 | $1M | +113,500 | +$24K |
| CATBUSD - Astria Therapeutics | 0.29% | Add +82.7% | 127,653 | $8.33 | $1M | +57,770 | +$134K |
| ACRV - Acrivon Therapeutics | 0.27% | Add +50.3% | 76,852 | $12.96 | $996K | +25,704 | +$347K |
| Surface Oncology | 0.26% | Hold | 1,100,000 | $0.8696 | $957K | — | — |
| Syros Pharmaceuticals | 0.23% | Hold | 265,878 | $3.15 | $838K | — | — |
| Pardes Biosciences | 0.21% | Reduce −10.2% | 430,291 | $1.81 | $779K | −49,095 | +$146K |
| Nevro | 0.19% | New | 28,000 | $25.42 | $712K | +28,000 | +$712K |
| Elevation Oncology | 0.19% | New | 450,000 | $1.52 | $684K | +450,000 | +$684K |
| Neuronetics | 0.18% | Hold | 313,717 | $2.15 | $674K | — | — |
| Spruce Biosciences | 0.18% | Hold | 312,000 | $2.15 | $671K | — | — |
| BHVN - Biohaven | 0.14% | Reduce −91.0% | 21,113 | $23.92 | $505K | −214,500 | −$3M |
| Masimo | 0.13% | Hold | 3,000 | $164.55 | $494K | — | — |
| CMPX - Compass Therapeutics | 0.10% | Hold | 116,882 | $3.18 | $372K | — | — |
| Karyopharm Therapeutics | 0.09% | Hold | 192,678 | $1.79 | $345K | — | — |
| Nextcure | 0.09% | Hold | 187,696 | $1.80 | $338K | — | — |
| Adaptimmune Therapeutics | 0.09% | Hold | 351,064 | $0.9250 | $325K | — | — |
| Medicenna Therapeutics | 0.09% | Hold | 660,000 | $0.4817 | $318K | — | — |
| PRCT - Procept Biorobotics | 0.08% | New | 8,000 | $35.35 | $283K | +8,000 | +$283K |
| Kinnate Biopharma | 0.07% | Reduce −1.0% | 80,179 | $3.03 | $243K | −829 | −$263K |
| Compugen | 0.06% | Hold | 205,202 | $1.14 | $234K | — | — |
| Holding | 0.05% | Hold | 140,000 | $1.41 | $197K | — | — |
| Spero Therapeutics | 0.05% | Hold | 125,000 | $1.45 | $181K | — | — |
| INGN - Inogen | 0.05% | Hold | 15,000 | $11.55 | $173K | — | — |
Showing top 50 of 72 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2023 Q1
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Cardiovascular Systems | 1.71% | Exit | 0 | $19.86 | $6M | −286,988 | −$6M |
| APLSUSD - Apellis Pharmaceuticals | 1.14% | Exit | 0 | $65.96 | $4M | −57,746 | −$4M |
| Theseus Pharmaceuticals | 0.35% | Exit | 0 | $8.88 | $1M | −131,025 | −$1M |
| ORIC - Oric Pharmaceuticals | 0.29% | Exit | 0 | $5.70 | $971K | −170,326 | −$971K |
| Genfit S A | 0.24% | Exit | 0 | $4.10 | $812K | −197,940 | −$812K |
| Ikena Oncology | 0.12% | Exit | 0 | $3.45 | $390K | −112,936 | −$390K |
| Reunion Neuroscience | — | Exit | 0 | $0.7144 | $9K | −12,598 | −$9K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 88 | $524M | +19.1% | 13F-HR | 8/14/2026 | 000138993326000006 |
| 2026 Q1 | 83 | $440M | +2.1% | 13F-HR | 5/15/2026 | 000138993326000004 |
| 2025 Q4 | 77 | $431M | +6.4% | 13F-HR | 2/17/2026 | 000138993326000002 |
| 2025 Q3 | 75 | $405M | +11.9% | 13F-HR | 11/14/2025 | 000138993325000008 |
| 2025 Q2 | 76 | $362M | +2.5% | 13F-HR | 8/14/2025 | 000138993225000011 |
| 2025 Q1 | 83 | $353M | −10.2% | 13F-HR | 5/15/2025 | 000138993325000002 |
| 2024 Q4 | 82 | $393M | −7.1% | 13F-HR | 2/14/2025 | 000138993225000004 |
| 2024 Q3 | 84 | $423M | +1.0% | 13F-HR | 11/14/2024 | 000138993224000020 |
| 2024 Q2 | 83 | $419M | −4.6% | 13F-HR | 8/14/2024 | 000138993224000016 |
| 2024 Q1 | 72 | $439M | +5.3% | 13F-HR | 5/15/2024 | 000138993224000012 |
| 2023 Q4 | 76 | $417M | +29.9% | 13F-HR | 2/14/2024 | 000138993224000004 |
| 2023 Q3 | 75 | $321M | −12.3% | 13F-HR | 11/14/2023 | 000138993223000010 |
| 2023 Q2 | 73 | $366M | +9.6% | 13F-HR | 8/14/2023 | 000138993323000008 |
| 2023 Q1 | 72 | $334M | −5.9% | 13F-HR | 5/15/2023 | 000138993323000006 |
| 2022 Q4 | 79 | $355M | −4.6% | 13F-HR | 2/14/2023 | 000138993323000002 |
| 2022 Q3 | 87 | $372M | +1.4% | 13F-HR | 11/14/2022 | 000138993322000010 |
| 2022 Q2 | 90 | $367M | −4.4% | 13F-HR | 8/15/2022 | 000138993322000008 |
| 2022 Q1 | 94 | $384M | −3.5% | 13F-HR | 5/16/2022 | 000138993322000006 |
| 2021 Q4 | 87 | $398M | +5.6% | 13F-HR | 2/14/2022 | 000138993322000002 |
| 2021 Q3 | 80 | $377M | — | 13F-HR | 11/15/2021 | 000138993321000011 |
About
DAFNA Capital Management LLC
20 processed 13Fs on this site · 2021 Q3–2026 Q2